| Literature DB >> 33923030 |
Débora Bublitz Anton1, Rodrigo Gay Ducati1, Luís Fernando Saraiva Macedo Timmers1,2, Stefan Laufer3, Márcia Inês Goettert1,2.
Abstract
The p38δ mitogen-activated protein kinase is an important signal transduction enzyme. p38δ has recently emerged as a drug target due to its tissue-specific expression patterns and its critical roles in regulation of cellular processes related to cancer and inflammatory diseases, such as cell proliferation, cell migration, apoptosis, and inflammatory responses. However, potent and specific p38δ inhibitors have not been defined so far. Moreover, in cancer disease, p38δ appears to act as a tumor suppressor or tumor promoter according to cancer and cell type studied. In this review, we outline the current understanding of p38δ roles in each cancer type, to define whether it is possible to delineate new cancer therapies based on small-molecule p38δ inhibitors. We also highlight recent advances made in the design of molecules with potential to inhibit p38 isoforms and discuss structural approaches to guide the search for p38δ inhibitors.Entities:
Keywords: MAPK13; SAPK4; cancer; p38 delta; p38δ MAPK; p38δ inhibitors
Year: 2021 PMID: 33923030 DOI: 10.3390/cancers13092077
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639